Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study.

Jade DubutValérie GoinCloé DerrayYoann HugueninMathieu Fiore

Published in: Journal of thrombosis and haemostasis : JTH (2024)

Concizumab enhanced thrombin generation, decreased the ROTEM CT, improved thrombus formation under flow, and reduced clot lysis. Our results demonstrate the potential of concizumab for subcutaneous prophylaxis in GT patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
computed tomography
prognostic factors
image quality
contrast enhanced
patient reported outcomes
climate change
pet ct